Related Experiment Videos

The Jupiter study, CRP screening, and aggressive statin therapy-implications for the primary prevention of

Richard Kones1

  • 1Cardiometabolic Research Institute, Houston, TX 77054 USA. drrkones@comcast.net

Therapeutic Advances in Cardiovascular Disease
|May 23, 2009
PubMed

Insights

High-sensitivity C-reactive protein (hs-CRP) predicts cardiovascular risk. The Jupiter trial found rosuvastatin significantly reduced cardiovascular events and mortality in individuals with elevated hs-CRP and low LDL cholesterol.

Area of Science:

  • Cardiovascular Medicine
  • Clinical Trials
  • Pharmacology

Background:

  • High-sensitivity C-reactive protein (hs-CRP) is a key biomarker for cardiovascular risk.
  • Current guidelines recommend statin therapy for cardiovascular disease (CVD) prevention, but optimal use in individuals with elevated hs-CRP requires further investigation.

Purpose of the Study:

  • To evaluate the efficacy and safety of rosuvastatin in apparently healthy individuals with elevated hs-CRP and low LDL cholesterol.
  • To determine if hs-CRP can effectively identify individuals who would benefit from statin therapy.

Main Methods:

  • The Jupiter trial randomized 17,802 participants with hs-CRP > 2.0 mg/L and LDL-C < 130 mg/dL to receive rosuvastatin 20 mg daily or placebo.
  • Participants were followed for a primary endpoint including nonfatal myocardial infarction, stroke, arterial revascularization, unstable angina hospitalization, or cardiovascular death.

Main Results:

  • Rosuvastatin significantly reduced the primary composite endpoint by 47% (P<0.001).
  • Specific reductions were observed for nonfatal myocardial infarction (55%), nonfatal stroke (48%), and cardiovascular death (20%).
  • Rosuvastatin also lowered hs-CRP by 37% and LDL-C by 50%, with a small increase in physician-reported diabetes.

Conclusions:

  • In apparently healthy individuals with elevated hs-CRP and low LDL cholesterol, rosuvastatin significantly reduces major cardiovascular events and mortality.
  • These findings support the use of statins for primary prevention in a broader population identified by hs-CRP levels.
  • The Jupiter trial data suggest that hs-CRP is a valuable tool for cardiovascular risk stratification and guiding statin therapy decisions.

Related Concept Videos

Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT01:25

Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT

Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...